M&T Bank Corp increased its stake in shares of Edwards Lifesciences Corp. (NYSE:EW) by 5.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,190 shares of the medical research company’s stock after buying an additional 1,910 shares during the period. M&T Bank Corp’s holdings in Edwards Lifesciences Corp. were worth $4,121,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in shares of Edwards Lifesciences Corp. during the second quarter valued at about $100,000. Quadrant Capital Group LLC increased its stake in shares of Edwards Lifesciences Corp. by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock valued at $106,000 after buying an additional 25 shares during the period. Exane Derivatives purchased a new stake in shares of Edwards Lifesciences Corp. during the second quarter valued at about $118,000. Spirit of America Management Corp NY purchased a new stake in shares of Edwards Lifesciences Corp. during the third quarter valued at about $121,000. Finally, Duncker Streett & Co. Inc. increased its stake in shares of Edwards Lifesciences Corp. by 10.5% in the second quarter. Duncker Streett & Co. Inc. now owns 1,264 shares of the medical research company’s stock valued at $126,000 after buying an additional 120 shares during the period. Institutional investors own 83.08% of the company’s stock.

Institutional Ownership by Quarter for Edwards Lifesciences Corp. (NYSE:EW)

Shares of Edwards Lifesciences Corp. (NYSE:EW) traded down 0.47% during trading on Tuesday, hitting $83.90. 2,768,398 shares of the stock traded hands. The company has a 50 day moving average price of $99.49 and a 200 day moving average price of $106.55. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of 33.16 and a beta of 0.71. Edwards Lifesciences Corp. has a 12 month low of $72.20 and a 12 month high of $121.75.

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 25th. The medical research company reported $0.68 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.68. The firm had revenue of $739.40 million for the quarter, compared to analysts’ expectations of $749.14 million. Edwards Lifesciences Corp. had a net margin of 19.24% and a return on equity of 24.32%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter last year, the company posted $0.54 EPS. Analysts anticipate that Edwards Lifesciences Corp. will post $2.88 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at http://www.dailypolitical.com/2016/11/29/mt-bank-corp-buys-1910-shares-of-edwards-lifesciences-corp-ew.html.

EW has been the subject of several research reports. Canaccord Genuity set a $140.00 price objective on shares of Edwards Lifesciences Corp. and gave the stock a “buy” rating in a research report on Monday. Evercore ISI restated a “hold” rating on shares of Edwards Lifesciences Corp. in a research report on Monday. Northland Securities upgraded shares of Edwards Lifesciences Corp. from a “market perform” rating to an “outperform” rating and set a $105.00 price objective for the company in a research report on Tuesday, November 8th. Leerink Swann restated an “outperform” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Friday, October 28th. Finally, BTIG Research restated a “buy” rating and set a $110.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Friday, October 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-two have assigned a buy rating to the company’s stock. Edwards Lifesciences Corp. presently has an average rating of “Buy” and an average target price of $117.68.

In related news, VP Larry L. Wood sold 13,257 shares of the stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $119.27, for a total transaction of $1,581,162.39. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 49,100 shares of the stock in a transaction on Thursday, October 27th. The shares were sold at an average price of $92.77, for a total transaction of $4,555,007.00. The disclosure for this sale can be found here. Insiders own 2.37% of the company’s stock.

Edwards Lifesciences Corp. Company Profile

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp. (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.